Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on February 7, 2023

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference

Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress

Anavex Life Sciences to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results

Anavex Life Sciences to Participate at the BTIG Biotechnology Conference 2022

Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022

Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Second Quarter Financial Results

Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tues. May 10, 2022

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting